Merck & Co. Inc. buy stratec
Start price
06.10.19
/
50%
€77.60
Target price
04.11.21
€90.00
Performance (%)
3.09%
End price
05.11.21
€80.00
Summary
This prediction ended on 05.11.21 with a price of €80.00. With a performance of 3.09%, the BUY prediction by stratec for Merck & Co. Inc. closed with a slight gain. A total of €4.31 was paid as dividends for this prediction. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merck & Co. Inc. | 1.887% | 1.887% | 13.143% | 85.538% |
| iShares Core DAX® | -2.196% | -0.532% | 12.492% | 15.176% |
| iShares Nasdaq 100 | -0.074% | 1.843% | 40.598% | 43.702% |
| iShares Nikkei 225® | -2.154% | -1.109% | 22.295% | 3.143% |
| iShares S&P 500 | -0.501% | 1.475% | 28.278% | 41.943% |
Comments by stratec for this prediction
In the thread Merck & Co. Inc. diskutieren
Merck’s (NYSE:MRK) Keytruda cancer drug will be the world's best selling drug by 2025, with projected annual sales of $22.5B, according to a new report from the GlobalData research firm.
Keytruda already has received 22 approvals for oncology indications by the Food and Drug Administration, and the drug is involved in more than 1,000 clinical trials; if only 10% of those trials hit, approvals for Keytruda will climb exponentially.
In the thread Trading Merck & Co. Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten